Anaphylaxis News and Research

RSS
Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.
Trial tests efficacy and safety of NVX-CoV2373 COVID-19 vaccine among adolescents

Trial tests efficacy and safety of NVX-CoV2373 COVID-19 vaccine among adolescents

The incidence rates of adverse events of special interest in COVID-19 vaccinated and non-vaccinated persons

The incidence rates of adverse events of special interest in COVID-19 vaccinated and non-vaccinated persons

Updated guidelines on the Valneva SARS-CoV-2 vaccine

Updated guidelines on the Valneva SARS-CoV-2 vaccine

Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID

Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID

Inappropriate antibiotic prescriptions for children associated with excess health-care costs

Inappropriate antibiotic prescriptions for children associated with excess health-care costs

Using microfluidics and magnets to isolate rare, allergen-reactive white blood cells

Using microfluidics and magnets to isolate rare, allergen-reactive white blood cells

Risk for anaphylaxis higher with two intravenous iron formulations

Risk for anaphylaxis higher with two intravenous iron formulations

Clinical trial shows encouraging results with fecal microbiota transplants for peanut-allergic patients

Clinical trial shows encouraging results with fecal microbiota transplants for peanut-allergic patients

Low risk of second allergic reaction after SARS-CoV-2 vaccination

Low risk of second allergic reaction after SARS-CoV-2 vaccination

Assessing potential allergic reactions in COVID-19 vaccinated patients

Assessing potential allergic reactions in COVID-19 vaccinated patients

Two peanut allergy treatments for children found to be highly effective at inducing remission

Two peanut allergy treatments for children found to be highly effective at inducing remission

Vaccine hypersensitivity in children

Vaccine hypersensitivity in children

Study shows efficacy, safety of oral immunotherapy in one- to three-year-olds with peanut allergy

Study shows efficacy, safety of oral immunotherapy in one- to three-year-olds with peanut allergy

Oral penicillin may be a safer option for people with high-risk rheumatic heart disease

Oral penicillin may be a safer option for people with high-risk rheumatic heart disease

Study evaluates acute and long-term adverse events following immunization with COVID-19 Moderna vaccine

Study evaluates acute and long-term adverse events following immunization with COVID-19 Moderna vaccine

International approaches to tackling food fraud

International approaches to tackling food fraud

Mathematical modeling the vaccination of children against SARS-CoV-2

Mathematical modeling the vaccination of children against SARS-CoV-2

Oral bacteria-based SARS-CoV-2 vaccine platform

Oral bacteria-based SARS-CoV-2 vaccine platform

Clear, specific product labeling for sesame is crucial to prevent anaphylaxis

Clear, specific product labeling for sesame is crucial to prevent anaphylaxis

Temporary suspension of 15-minute observation period after vaccination to accelerate booster program

Temporary suspension of 15-minute observation period after vaccination to accelerate booster program